Active, not yet recruiting
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
NCT No.: NCT05312879
Study Type: INTERVENTIONAL
Phase:
Phase II
Region: California - Northern
Acronym:
Official Title
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Purpose
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 18 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Detailed Description
Eligibility Criteria
Inclusion Criteria
- APOL1 genotype of G1/G1, G2/G2, or G1/G2
|
-
Proteinuric kidney disease
|
Exclusion Criteria
- Solid organ or bone marrow transplant
|
-
Uncontrolled hypertension
|
-
Diagnosis of diabetes mellitus
|
-
Known underlying cause of kidney disease including but not limited to sickle cell disease
|
-
Please contact study team, other protocol defined Inclusion/Exclusion criteria apply
|
Keywords and/or Specific Medical Conditions
Sponsors
- Vertex Pharmaceuticals Incorporated
|
|